Contract sales & marketing

Eversana expands Asian footprint with four new offices

12-Aug-2019 By Vassia Barba

Eversana looks to enhance its service in Asia and meet ‘increased’ demand with new offices in Singapore, Mumbai, Shanghai, and Tokyo.

Eversana, Cryoport partner on regenerative medicine supply chain

16-Jul-2019 By Vassia Barba

Eversana adopts Cryoport’s full suite of logistics services, in an alliance expected to ‘drive synergistic growth’ for both companies and answer regenerative medicine demands.

People on the Move: Outsourcing-Pharma roundup May ‘19

31-May-2019 By Melissa Fassbender

This month’s roundup includes the first CFO for CytoReason, a new CEO at Certara and Factory-CRO, as well as an expanded leadership team at BioDuro, among other people on the move in May.

Science Exchange integrates WuXi LabNetwork into its marketplace

26-Mar-2019 By Maggie Lynch

WuXi LabNetwork enters an agreement with Science Exchange enabling users to order compounds directly following an increased demand for specialty chemicals.

Lonza teams with hospital to produce CAR-T cells at point-of-care

18-Mar-2019 By Maggie Lynch

Lonza and Israel-based Sheba Medical collaborate to use the CDMO’s manufacturing platform for point-of-care genetically engineered human CAR-T cell production.

People on the Move: Outsourcing-Pharma roundup February ‘19

01-Mar-2019 By Melissa Fassbender

Parexel boosts its oncology team, Premier Research has a new COO joining from PPD, and SGS names a new biologics manager, among other new hires in February.

Lonza, Takeda reach regulatory milestone in oncology tie-up

17-Jan-2019 By Maggie Lynch

Lonza provided development, manufacturing, and clinical packaging services for Takeda’s Alunbrig, which has received EMA marketing authorization.

2018 regulatory round-up: Patient safety, data transparency, innovative trial designs

18-Dec-2018 By Melissa Fassbender

Global regulatory agencies had a busy 2018. Here, we take a look back at some of the key developments throughout the year, as the industry navigated challenging politics, pressure to increase transparency, and the rapidly evolving digital health space.

PE firm merging companies to create ‘one stop shop’ for medical affairs

11-Dec-2018 By Melissa Fassbender

The owners of Synteract, Amulet Capital Partners, have acquired a global health communications and market access group with plans to merge it with Peloton Advantage, which it purchased earlier this year.

Syneos revenue tops $1bn in Q3

19-Nov-2018 By Melissa Fassbender

Strong collaboration across the company’s clinical, commercial, and integration solutions teams led to a “solid performance,” said Syneos CEO Alistair MacDonald.

People on the Move: Outsourcing-Pharma roundup August '18

07-Sep-2018 By Melissa Fassbender

This month marked the effective start date for Parexel's new executive VP and CFO Greg Rush, who joins August's People on the Move with several other c-suite hires, including a new CEO at Citoxlab and COO at ProSciento.

DIA 2018

The nexus of innovation, policy improvements changing at never-before-seen pace: DIA

10-Jul-2018 By Melissa Fassbender

Cross-industry discussion is expanding from early discovery to post-licensing challenges – as the nexus of innovation and policy improvements is rapidly changing, says DIA executive.

Life science advances and gender equity on the program for DIA 2018

19-Jun-2018 By Melissa Fassbender

This year’s DIA Global Annual Meeting will focus on the latest global trends and showcase the "diverse group of key individuals driving the life science ecosystem forward," says DIA Americas managing director.

State of the Industry

State of the Industry: Taking the pulse of the contract services market

11-Jun-2018 By Melissa Fassbender

Following on from the success of last year's survey, Outsourcing-Pharma is running another 'state of the industry' survey to gauge views about the current state of the pharmaceutical contract services industry.

Commercial Trends Forecast: ‘R&D is transforming into R&D&C’

13-Mar-2018 By Melissa Fassbender

The R&D playbook is evolving as the industry looks to break down the silos between clinical and commercial operations – bringing commercial voices to the earliest phases of asset development.